Abstracts tagged "Knee and clinical trials"

Abstract Number: 1596 • 2012 ACR/ARHP Annual Meeting
Strontium Ranelate in Knee Osteoarthritis Trial (SEKOIA): A Structural and Symptomatic Efficacy
Jean-Yves Reginster¹, R. Chapurlat², Claus Christiansen³, H. Genant⁴, N. Bellamy⁵, W. Bensen⁶, F. Navarro⁷, J. Badurski⁸, E. Nasonov⁹, X. Chevalier¹⁰, PN. Sambrook¹¹, T. Spector¹² and Cyrus Cooper¹³, ¹Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ²Service de Rhumatologie et Pathologie Osseuse, INSERM UMR 1033 and Université de Lyon, Hôpital Edouard Herriot, Lyon, France, ³CCBR, Ballerup, Denmark, ⁴Radiology, Medicine and Orthopaedic Surgery University of California and Synarc, San Francisco, CA, ⁵CONROD. The University of Queensland, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia, ⁶St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁷Servicio de Reumatologia, H. Universitario Virgen de la Macarena, Sevilla, Spain, ⁸Center of Osteoporosis and Osteo-articular Diseases, Bialystock, Poland, ⁹ARBITER, Inst of Rheumatology, Moscow, Russia, ¹⁰Service de Rhumatologie, Hôpital Henri-Mondor, Creteil, France, ¹¹Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia, ¹²Dept of Twin Research and Genetic Epidemiology, King's College London, St. Thomas Campus, London, United Kingdom, ¹³NDORMS; MRC Lifecourse Epidemiology Unit, University of Oxford; Southampton General Hospital, Southampton, United Kingdom
Background/Purpose: Treatments for osteoarthritis focus on improving symptoms through non-pharmacological and pharmacological approaches. Strontium ranelate (SrRan), a treatment for osteoporosis, was shown to stimulate cartilage…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].